TrialInternational journal of chronic obstructive pulmonary disease2016

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).

Kai-Michael Beeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.